Form 4: Intra-Cellular Therapies Acquired by Johnson & Johnson for $132 Per Share

Joel S. Marcus reports the disposition of Intra-Cellular Therapies shares and derivative securities following the company's merger with a Johnson & Johnson subsidiary at a price of $132 per share.

Summary

• Joel S. Marcus, a director of Intra-Cellular Therapies, Inc., reported the disposition of his shares and derivative securities following the company's merger with Fleming Merger Sub, Inc., a wholly-owned subsidiary of Johnson & Johnson.
• The merger became effective on April 2, 2025.
• Each share of Intra-Cellular Therapies common stock was converted into the right to receive $132 in cash.
• Marcus disposed of 48,238 shares of common stock and 10,000 shares held indirectly through Alexandria Real Estate Equities, Inc.
• Stock options with an exercise price less than $132 were canceled and converted into the right to receive cash equal to the difference between $132 and the exercise price.
• Restricted stock units (RSUs) were canceled and converted into the right to receive $132 per share, with RSUs granted in 2025 payable at the original vesting date, subject to accelerated vesting in certain circumstances.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reports the completion of a merger, which typically results in a positive outcome for shareholders who receive a cash payout. The filing itself is a routine event following the merger.

Positives

• The merger provided a cash payout of $132 per share for Intra-Cellular Therapies shareholders.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

The acquisition of Intra-Cellular Therapies by Johnson & Johnson reflects ongoing consolidation trends in the pharmaceutical industry, where larger companies acquire smaller firms with promising drug candidates or technologies.

Comparison to Industry Standards

• Merger and acquisition transactions in the pharmaceutical industry often involve a premium paid to the target company's shareholders.
• The $132 per share price represents a premium over Intra-Cellular Therapies' previous trading price, which is typical in such deals.
• Comparable transactions include Pfizer's acquisition of Arena Pharmaceuticals and Bristol Myers Squibb's acquisition of MyoKardia, both of which involved significant premiums.

Stakeholder Impact

• Shareholders received $132 per share in cash.
• Employees' future is now tied to Johnson & Johnson.
• The company now operates as a wholly-owned subsidiary of Johnson & Johnson.

Key Dates

Keywords

Merger, Acquisition, Intra-Cellular Therapies, Johnson & Johnson, Form 4, Beneficial Ownership, Joel S. Marcus, ITCI